Replies to post #484734 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

The patent doesn't mean much if trials are not run. The clock is ticking on IP protection and the real challenge is executing not patenting. PD trial still not started. "Mystery" indication not started. Rett apparently abandoned. 3-71 additional trials not begun. There has to be more energy put into turning Anavex potential into reality.

[falconer66a]

The Real Anavex Story Will Be Modulation of Homeostasis

If every adult after forty takes a daily Anavex pill even if only $1 a pill the revenue would be astronomical. Who wouldn’t want a pill to drastically slow their brain from shrinking?

Presently, most of the public’s attention toward Anavex Life Sciences Corp focuses solely on the potential of the biotech start-up to gain regulatory approval to sell blarcamesine as a treatment for Alzheimer’s. Doubtless, that’s a big story, with potentially gigantic outcomes.

But to focus only on blarcamesine and Alzheimer’s misses the real story of Anavex science. It’s far more panoptic. It has the potential to revolutionize human health as much as did antibiotics in the last century.

The key is this. Activation of the sigma-1 receptor protein, by either blarcamesine or Anavex 3-71, favorably moderates a diversity of “downstream” cellular processes and functions; not just those that slow, delay, or prevent Alzheimer’s.

In all of us, with time, the cellular machinery operating in our cells begins to slow or malfunction. The root cause of aging.

But, as you might recall from a class in anatomy and physiology, organisms, organ systems, and cells have a multitude of processes that maintain physiological functions, to keep things operating properly in living organisms. These functions are “homeostatic,” from the root word “homeostasis.” “Homeo-” means “same.” “-stasis” means “state.” In the cell, organ, or organ system, keep things in the same healthful state.

And, by a diversity of mechanisms, that’s what sigma-1 receptor activation by an Anavex molecule obviates. It forces or allows the cell to restore things to their functionally healthful state.

I believe that preservation and restoration of cellular and organ homeostasis will be the real story of Anavex Life Sciences Corp. Most likely it will start with blarcamesine successfully preventing, delaying, or preventing Alzheimer’s disease; with other targeted pathologies to follow.

But, everyone ages; gets old, with progressing debilitations. As Anavex almost surely knows from closed door aging studies on animals used in aging studies, as the new patent application contends, blarcamesine can slow or prevent both brain atrophy and a host of other aging processes.

So, yes, in time it is highly likely that either blarcamesine or Anavex 3-71 will be broadly prescribed to otherwise fully healthful humans to slow, delay, or prevent a multitude of health problems otherwise attendant to aging.